8.26
-0.11
(-1.31%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 8.20 - 8.48 |
| 52 week | 6.18 - 8.48 |
| Open | 8.35 |
| Vol / Avg. | 1.80M/1.81M |
| Mkt cap | 1.16B |
| P/E | 5.43 |
| Div/yield | 0.15/7.26 |
| EPS | 1.52 |
| Shares | 140.00M |
| Beta | 0.50 |
| Inst. own | 95% |
Events
Aug 2, 2013
Q2 2013 PDL BioPharma Earnings Release
Jun 4, 2013
PDL BioPharma at Jefferies Global Healthcare Conference
May 21, 2013
PDL BioPharma Annual Shareholder Meeting
May 9, 2013
Q1 2013 PDL BioPharma Earnings Conference Call
May 3, 2013
Q1 2013 PDL BioPharma Earnings Release
Mar 6, 2013
PDL BioPharma at Cowen Health Care Conference
Mar 1, 2013
Q4 2012 PDL BioPharma Earnings Conference Call
Feb 27, 2013
PDL BioPharma at RBC Capital Markets' Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 58.22% | 56.52% |
| Operating margin | 92.18% | 93.20% |
| EBITD margin | - | 93.45% |
| Return on average assets | 72.36% | 77.05% |
| Return on average equity | - | - |
| Employees | 8 | - |
| Carbon Disclosure Rating | - | - |
Address
932 Southwood Blvd
INCLINE VILLAGE, NV 89451
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)
INCLINE VILLAGE, NV 89451
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Transcripts - SeekingAlpha
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.
Officers and directors
| John P. McLaughlin | President, Chief Executive Officer, Director | |
| Peter S. Garcia | Chief Financial Officer, Acting Chief Accounting Officer, Vice President | |
| Christopher Lewis Stone J.D. | Vice President, General Counsel, Secretary | |
| Danny Hart | Deputy General Counsel, Assistant Secretary | |
| Jody S Lindell | Independent Director | |
| Paul W. Sandman | Independent Director | |
| Harold E. Selick Ph.D. | Independent Director |